Arsenic exposure is a serious health hazard worldwide. We have previously established that it may result in immune suppression by upregulating Th2
cytokines while downregulating Th1
cytokines and causing lymphocytic death. Treatment modalities for
arsenic poisoning have mainly been restricted to the use of
chelating agents in the past. Only recently have combination
therapies using a
chelating agent in conjunction with other compounds such as
anti-oxidants,
micronutrients and various plant products, been introduced. In the present study, we used T11TS, a novel immune potentiating
glycopeptide alone and in combination with the sulfhydryl-containing
chelator, mono-iso-amyl-dimarcaptosuccinic
acid (
MiADMSA) as a therapeutic regimen to combat
arsenic toxicity in a mouse model. Results indicated that Th1
cytokines such as TNF-α, IFNγ,
IL12 and the Th2
cytokines such as
IL4,
IL6,
IL10 which were respectively downregulated and upregulated following
arsenic induction were more efficiently restored to their near normal levels by T11TS alone in comparison with the combined regimen. Similar results were obtained with the apoptotic
proteins studied, FasL, BAX, BCL2 and the
caspases 3, 8 and 9, where again T11TS proved more potent than in combination with
MiADMSA in preventing lymphocyte death. The results thus indicate that T11TS alone is more efficient in immune re-establishment after
arsenic exposureas compared to combination
therapy with T11TS+MiADMSA.